Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study.

Hartzell, Cheryl J; Szabova, Alexandra; Collins, Andrew B; Morel, Armand N; Mijatovic, Desimir; Goldschneider, Kenneth R

Hartzell, Cheryl J; Szabova, Alexandra; Collins, Andrew B; Morel, Armand N; Mijatovic, Desimir; Goldschneider, Kenneth R.

Afiliación

Hartzell CJ; Pain Management Center, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
Szabova A; Pain Management Center, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
Collins AB; Pain Management Center, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
Morel AN; Pain Management Center, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
Mijatovic D; Pain Management Center, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
Goldschneider KR; Pain Management Center, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.

Pediatr Dermatol ; 2024 Jul 25.

Article en En | MEDLINE | ID: mdl-39049669

ABSTRACT

ABSTRACT

INTRODUCTION:

At a single-center pediatric hospital, the neurokinin-1 receptor antagonist aprepitant was used to treat refractory pruritus in epidermolysis bullosa (EB) and atopic dermatitis (AD).

METHODS:

Thirty-seven patients were included (24 EB patients, 13 AD patients), ages 10 months to 37 years.

RESULTS:

58% (14/24) of patients with EB and 85% (11/13) of patients with AD reported aprepitant was effective in decreasing their pruritus, with age-related differences in efficacy observed in EB patients, and access to the medication by insurance denial or availability of the drug as a barrier to use.